Clinical trials for lung cancer

129 currently recruiting clinical trials

Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Targeted therapy
Systemic Treatment-Naive
Janssen
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive
Janssen
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy
AstraZeneca
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
ALK EGFR
Bristol-Myers Squibb
Bristol-Myers Squibb
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy
AstraZeneca
AstraZeneca
Phase 3 Lung cancer
#NCT06074588
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic ALK BRAF EGFR MET NTRK-1/2/3 RET ROS-1 Chemotherapy Targeted therapy
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
Institut Curie - Paris (Paris), Centre Hospitalier Universitaire de Rouen (Rouen), Centre Léon Bérard (Lyon), Institut Bergonié (Bordeaux)
Merck Sharp & Dohme LLC
Phase 3 Lung cancer
#NCT06561386
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic NTRK-1/2/3 PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) Systemic Treatment-Naive
ALK BRAF EGFR ROS-1 Immunotherapy Immunotherapy
Centre Hospitalier de la Côte Basque (Bayonne)
Bristol-Myers Squibb
Phase 3 Lung cancer
#NCT06216301
NSCLC (Non-Small Cell Lung Cancer) Squamous NSCLC Non-squamous NSCLC Metastatic None Systemic Treatment-Naive
ALK EGFR MET NTRK-1/2/3 RET ROS-1
Institut Curie - Paris (Paris)
NovoCure GmbH
Phase 3 Lung cancer
#NCT06875310
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C None Systemic Treatment-Naive
Targeted therapy Targeted therapy
CHRU de Nancy - Hôpitaux de Brabois (Vandœuvre-lès-Nancy), Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), Hôpital Cochin (Paris ), Centre Jean Perrin (Clermont Ferrand ), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Mirati Thérapeutique Inc.
Phase 3 Lung cancer
#NCT05920356
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C PDL1 Negative (< 1%) None Systemic Treatment-Naive
Targeted therapy Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Centre Hospitalier de Cornouaille (Quimper), Centre Antoine Lacassagne (Nice), Institut de Cancérologie et d’Hématologie Universitaire de Saint-Étienne (CHU Saint-Étienne) (Saint-Priest-en-Jarez), Centre Hospitalier Universitaire de Lille - Institut Cœur Poumon (Lille), Centre Hospitalier Universitaire de Nîmes (Nîmes) (and 24 more...)
Amgen